Article
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
The New England journal of medicine - 3 Aug 2017
Stone Richard M, Mandrekar Sumithra J, Sanford Ben L, Laumann Kristina, Geyer Susan, Bloomfield Clara D, Thiede Christian, Prior Thomas W, Döhner Konstanze, Marcucci Guido, Lo-Coco Francesco, Klisovic Rebecca B, Wei Andrew, Sierra Jorge, Sanz Miguel A, Brandwein Joseph M, de Witte Theo, Niederwieser Dietger, Appelbaum Frederick R, Medeiros Bruno C, Tallman Martin S, Krauter Jürgen, Schlenk Richard F, Ganser Arnold, Serve Hubert, Ehninger Gerhard, Amadori Sergio, Larson Richard A, Döhner Hartmut
Abstract excerpt
BACKGROUND: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would pr...
Topics
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- Cytarabine
- Daunorubicin
- Female
- Humans
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute